Cigarette smoking is associated with significant increases in the number of pulmonary mononuclear phagocytes and neutrophils. A potent chemoattractant for these cells is C5a, a peptide generated during complement (C) activation. We, therefore, investigated the possibility that cigarette smoke could activate the complement system in vitro. Our results show that factor(s) (mol wt < 1,000) present in an aqueous solution of whole, unfiltered cigarette smoke can deplete the hemolytic capacity of whole human serum in a dose-dependent manner. The particle-free, filtered gas phase of cigarette smoke is inactive. The smoke factor(s) do not activate serum C1, but do deplete serum C4 activity. Treatment of purified human C3 with whole smoke solution modifies the-molecule such that its subsequent addition to serum (containing Mg/EGTA to block the classical pathway) results in consumption of hemolytic complement by activation of the alternative pathway. Smoke-modified C3 shows increased anodal migration in agarose electrophoresis, but this is not due to proteolytic cleavage of the molecule as evidenced by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. In contrast to methylamine-treated C3, C3 treated with smoke is only partially susceptible to the action of the complement regulatory proteins Factors H and I. In addition, smoke-modified C3 has diminished binding to Factor H as compared with methylamine-treated C3. Finally, smoke-modified C3 incorporates ['4Cjmethylamine which suggests that the thiolester bond may be intact.
Introduction the pathogenesis of the disease. The characteristic histopathologic observation in the emphysematous lung is excessive tissue dissolution which is thought to result from an unrestrained proteolytic attack on lung interstitium, particularly the elastic fibers (reviewed in 2, 3). Neutrophils and mononuclear phagocytes (alveolar macrophages and monocytes) have been implicated as the source of this increased protease (primarily elastase) burden (4) (5) (6) . The lungs of cigarette smokers are known to contain significantly increased numbers of these elastase-bearing phagocytes (7, 8) , but the mechanism of this smoke-induced leukocyte recruitment is poorly understood.
Recently, efforts have focused on mechanisms whereby cigarette smoke may indirectly recruit phagocytic cells into the lung. Many of these studies have examined the elaboration of neutrophil chemoattractants by stimulated alveolar macrophages of smokers (9) (10) (11) (12) . In addition, proteolytic destruction of lung connective tissue may, in itself, contribute to the leukocyte recruitment. For example, proteolytically generated fragments of collagen (13) and fibronectin (14) have been demonstrated to be chemotactic for peripheral blood monocytes, and incubation of human elastin with neutrophil elastase results in the production of biologically active peptides which are also chemotactic for neutrophils and monocytes (15).
Less attention, however, has been paid to the possibility that leukocyte chemoattractants may be generated in the lung fluids of smokers as a direct result of complement (C)' activation by inhaled cigarette smoke. It is well documented that when the complement cascade is activated, the fifth component of complement (C5) is proteolytically cleaved, resulting in generation of the chemotactically active peptide C5a (reviewed in 16). C5a is one of the most potent neutrophil and monocyte chemoattractants yet described and is biologically active at picogram quantities. Moreover, a recent report demonstrates that physiological concentrations of nicotine enhance neutrophil responsiveness to C5a (17) .
We reported earlier that rats acutely exposed to cigarette smoke had significantly increased levels of chemotactic activity for neutrophils and monocytes in their lung fluids. However, prior depletion of circulating complement by treatment of the animals with cobra venom factor prevented this smoke-induced chemotactic activity (18) . In addition, others have recently demonstrated consumption of complement hemolytic activity in serum following its incubation with cigarette smoke condensate (19, 20) . Although suggestive, our preliminary studies and the others referred to above did not explore possible chemical mechanisms of complement activation by cigarette smoke.
Therefore, we undertook in vitro studies to investigate the effect of cigarette smoke on serum complement and purified complement components. In the present report, we show that incubation of whole human serum with an aqueous solution of unfiltered cigarette smoke depletes hemolytic activity. Serum Cl was not activated under these conditions; however, purified C3 preincubated with smoke solution and subsequently added to serum (containing 5 Factors H and I were purified as described (23). The highly purified Factor H used in our binding experiment (see below) was a generous gift from Dr. Michael Pangburn (Scripps Clinic and Research Foundation, La Jolla, CA).
Aggregated IgG. Human IgG was first isolated from serum by a single step procedure using DEAE Affi-Gel Blue, according to the manufacturer's specifications (Bio-Rad Laboratories, Inc., Richmond, CA). IgG was then aggregated by incubation at 63°C for 20 min at a concentration of 10 mg/ml, as described (24) . Particulate aggregates were removed by centrifugation at 200 g for 5 min and the supernate was used as soluble, aggregated IgG. Sera and antisera. A pool of normal human serum (NHS) was obtained from young, apparently healthy, nonsmoking volunteers.
Monospecific, polyvalent antisera to Clq, C3, and C4 were raised in New Zealand White rabbits by multiple subcutaneous and intramuscular injections of 0.1 mg of purified antigen in Freund's complete adjuvant. Antihuman C3 was also purchased from Cappel Laboratories (West Chester, PA). Antisera to Clr and CIs were raised in goats, and also purchased from Atlantic Antibodies (Scarborough, ME).
Protein determinations. Protein concentrations were determined by the method of Lowry (25) using bovine serum albumin as a reference standard. The concentration of C3 was also determined by measuring absorbance at 280 nm using an Ei"mof 9.7 as previously described (21). Before use, the cigarettes were thawed, and then rehumidified for 24 h at 60% relative humidity in a sealed chamber at room temperature. The smoking regimen, based on the standard smoking cycle (27) , was as follows: 35 ml of tobacco smoke was drawn into the syringe in a 2-s puff and then slowly bubbled into the buffer. One puff of smoke per minute was drawn until a 5-cm butt length of cigarette was consumed (usually eight or nine puffs). In this manner, the smoke of six cigarettes was bubbled through 1.0 ml of PBS at 370C, after which the solution was decanted to a new tube to remove the accumulated tar and large particulate matter. Since the final smoke solutions were slightly acidic, the pH was readjusted with 1.0 N NaOH to match that of the starting buffer. Smoke solutions prepared in this manner varied only ±10% in their ability to consume 50% of serum complement.
In some experiments, the whole aqueous smoke solutions were exhaustively dialylzed before use against PBS at 40C using Spectra-Por 6 dialysis tubing (mol wt limit = 1000; Spectrum Medical Industries, Inc., Los Angeles, CA) and these were designated as dialyzed smoke solutions. Aqueous solutions of the particle-free, gas phase of cigarette smoke were also prepared exactly as described above except that a Cambridge filter pad (44-mm diam, 1.5-mm thick, 0.22 aim pore size; Phipps and Bird, Inc., Richmond, VA) was inserted between the cigarette and the 3-way stopcock. The filter pad was replaced after each cigarette was consumed.
Aliquots of each smoke solution were tested for endotoxin contamination using the Limulus Amebocyte Lysate kit (M. A. Bioproducts, Walkersville, MD) and were found to be negative. After preparation, all smoke solutions were either stored at -850C or used immediately.
Treatment of C3 and NHS with smoke solutions. Purified C3 and NHS were treated with smoke solutions, methylamine, or PBS (the amounts are described in the appropriate section of Results) for 60 min at 370C. The mixtures were then exhaustively dialyzed against PBS at 40C, using a dialysis membrane with a mol wt limit of 50,000 (Spectrum Medical Industries, Inc.), to remove unreacted, dialyzable smoke components or excess methylamine. Preparations were stored at -850C or used immediately.
Electrophoretic procedures. C3 and NHS, treated as above, were electrophoresed at 3-4 V/cm for 2.5 h at room temperature in 1% agarose (Seakem LE, FMC Corp., Rockland, ME) using 0.1 M barbital buffer (pH 8.6). After electrophoresis, C3 was visualized with a monospecific, polyvalent antihuman C3. Electrophoresis in polyacrylamide gel containing sodium dodecyl sulfate (SDS-PAGE) was performed according to the method of Laemmli (28) . Staining of gels for proteins was performed using Coomassie Brilliant blue R-250 or Amido black lOB (Bio-Rad Laboratories, Inc.).
Hemolytic assays. Sheep erythrocytes sensitized with rabbit antisheep erythrocyte antibody (EA) and EA coated with human Cl (EAC1) were prepared according to established methods (29) . Materials used in the preparation of EA and EAC1 were purchased from Cordis Laboratories, Inc. (Miami, FL). Unsensitized rabbit erythrocytes (ER) were freshly isolated from a New Zealand White rabbit and then washed several times with cold Mg-GVB. Hemolytic titration of serum C4 was performed as previously described (29) . Depletion of serum hemolytic activity was measured by adding various amounts of smoke solutions, methylamine, and/or PBS to 0.1 ml of NHS so that the final volume of the mixture was 0.2 ml. After a 60-min incubation at Cigarette Smoke Activates Complement 370C, 0.02 ml of the reaction mixture was removed and added to 0.1 ml of EA (5 X 108/ml), the volume was adjusted to 0.4 ml with GVB2+, and the incubation was continued for an additional 60 min at 370C.
The hemolytic reaction was terminated by adding 1.6 ml of ice-cold GVB2+, the mixtures were centrifuged, and the percentage of hemolysis was measured as the absorbance of free hemoglobin in the supernate at 412 nm. The percent lysis of EA incubated with 0.01 ml of untreated NHS was used as a reference for 0% depletion of hemolytic activity. Since whole smoke solution has its own color, all hemolytic assays had smoke-color controls consisting of smoke solution, EA, and GVB2+. This absorbance value was subtracted from the smoke-treated experimental samples.
Activation of the alternative pathway was measured by pretreating 0.05 ml of purified C3 (1 mg/ml) with various amounts of smoke solutions, methylamine, and/or PBS so that the final volume was 0.1 ml. Following a 60-min incubation at 370C, 0.1 ml of NHS containing 5 mM Mg-EGTA was added to each mixture and the reaction was allowed to proceed for an additional 60 min at 370C. Next, 0.1 ml of each mixture was removed and added to 0.1 ml of ER (5 X 108/ml), the volume was adjusted to 0.4 ml with Mg-GVB, and the incubation continued at 370C for 60 min. The reaction was stopped by addition of 1.0 ml of ice-cold Mg-GVB. After a low speed centrifugation, the absorbance of the supernate was measured as before at 412 nm.
Immunochemical determination of Cl activation in serum. NHS was incubated with an equal volume of whole smoke solution, PBS, or aggregated IgG (2 mg/ml) for 60 min at 370C. These mixtures were then analyzed by single radial immunodiffusion against anti-Clr. The immunodiffusion slides contained 1% agarose in 0.03 M potassium phosphate (pH 8.0), 0.1 M NaCl, and 0.01 M EDTA, and the appropriate dilution of anti-Clr as previously described (30) . Double (Ouchterlony) immunodiffusion analysis was also carried out on these samples using 0.8% agarose in veronal-buffered saline (pH 7.2) containing 2.5 mM CaCl2 and 0.09 M NaCl, and precipitin lines were developed with monospecific, polyvalent antihuman Clq, Clr, and Cls.
Effect of Factors H and I on treated C3. Samples of C3, 0.1 ml at 1.6 mg/ml, were treated as above with smoke solution, methylamine, or PBS. The treated C3 (160 tig) was then reacted for 45 min at 37°C with physiological concentrations of Factors H (50 ug) and I (3.4 Mg) in a total volume of 0.2 ml. C3 cleavage products were subsequently visualized by SDS-PAGE under reducing conditions.
Binding of Factor H to treated C3. Factor H was radioiodinated (0.5 mCi/mg) using '25I-Bolton-Hunter reagent (New England Nuclear, Boston, MA) according to the manufacturer's specifications. Sheep erythrocytes coated with C3b (EC3b) were prepared as described in (31) . A competitive 1251-labeled Factor H binding assay was then carried out to test for activated C3 after treatment with smoke solution, methylamine, or PBS, according to the method of Pangburn and Miuler-Eberhard (32) . C3b, generated by treating C3 with trypsin (see above), was used as the positive control in this assay.
Treatment of C3 with radiolabeled methylamine or iodoacetamide. 0.5 ml of C3 (2.5 mg/ml), pretreated with smoke solution, methylamine, or PBS as described above, was reacted with 4 mM ['4C]methylamine (46 mCi/mmol; New England Nuclear) for 4 h at 37°C. Excess isotope was subsequently removed by dialysis against PBS at 4°C. Approximately 0.32 mg of each C3 was then added to 10 ml of Dimiscint (National Diagnostics, Somerville, NJ) and the uptake of labeled methylamine was determined by liquid scintillation counting.
Radioalkylation of C3 pretreated with smoke, methylamine, or PBS was carried out using ["C]iodoacetamide (23.6 mCi/mmol; New England Nuclear) according to the method of Janatova et al. (33) .
Results
Effect of aqueous cigarette smoke on serum hemolytic activity. Fig. 1 demonstrates that aqueous, unfiltered cigarette smoke solution depletes the hemolytic capacity of NHS in a dosedependent fashion and in a manner similar to that which Following an incubation at 370C for 60 min, 0.02 ml of each mixture was removed and added to 0.1 ml of EA (5 X 108/ml) and the final volume was adjusted to 0.4 ml with GVB2 . After an additional 60-min incubation at 370C, the reaction was terminated by adding 1.6 ml of ice-cold GVB2+. Hemolysis was measured as the absorbance at 412 nm of free hemoglobin in the supernate. Data are expressed as the percent of serum hemolytic activity depleted, using untreated serum as the 0% reference (100% hemolysis). Methylamine (------); whole, aqueous smoke solution ( * -); dialyzed smoke (-* -); aqueous, gas phase of smoke (-0-); PBS (-o-).
occurs after treatment of serum with methylamine, a nucleophile known to activate the alternative pathway of complement by cleaving the thiolester bond in C3 (31) . This smoke-induced depletion is not due to endotoxin contamination because smoke solutions were determined to be endotoxin negative using the Limulus assay. In addition, loss of serum hemolytic activity is not an artifact due to direct effects of smoke on the EA, because smoke-treated and untreated EA were equally susceptible to complement-mediated lysis by NHS. Dialyzed smoke solutions (1000-mol wt limit membrane) did not deplete serum complement activity. Similarly, the particle-free, aqueous gas phase of smoke had no effect on the hemolytic capacity of NHS. Finally, nicotine, ammonia, and cyanide, which are all present in relatively large quantities in cigarette smoke, failed to deplete serum hemolytic activity over a wide range of concentrations tested.
Effect of smoke on purified C3. Since smoke appeared to diminish serum hemolytic complement activity, we chose next to examine the effect of smoke on purified C3 because (a) C3 is the complement component found in the highest concentration in serum and is essential for the activation of both the classical and alternative pathways, and (b) smoke contains a number of substances (including methylamine) which can potentially break the thiolester bond in C3 and activate the alternative pathway. Fig. 2 demonstrates that incubation of purified C3 with smoke solution modified the activity of the protein such that its subsequent addition to serum caused consumption of complement. Before incubation with smoke, the C3 used in this experiment was rigorously purified, as described in Methods, to free it from contaminating C3b and C3(H20), both of which can activate the alternative pathway. (---*--), or PBS (-o -); the final volume of the mixtures was then adjusted to 0.1 ml with PBS. Following a 60-min incubation at 370C, mixtures were exhaustively dialyzed against PBS at 40C in a 0.5-ml conical microtube. 0.1 ml of NHS containing 5 mM Mg-EGTA was then added to each sample and incubated for 60 min at 370C. 0.1 ml of each mixture was removed and added to 0.1 ml of ER (5 X 108/ml), the volume was adjusted to 0.4 ml with Mg-GVB, and samples were incubated for an additional 60 min at 370C. Hemolysis was measured as absorbance at 412 nm as before. Data are expressed as the percent consumption of hemolytic C in Mg-EGTA-treated serum, using untreated serum as the 0% reference (100% hemolysis).
Such purified C3, incubated with buffer, did not activate complement upon addition to serum. Since the C3 plus smoke mixtures were exhaustively dialyzed through large-pore membranes before their addition to serum, the resultant complement activation was due to modified C3 and not to residual active smoke components, because the latter are dialyzable through 1000-mol wt limit membranes (Fig. 1) . Also, because the serum contained Mg-EGTA to prevent classical pathway activation, the smoke-modified C3 apparently activated the alternative pathway. Under the same conditions, methylaminetreated C3 (a known activator of the alternative pathway) gave similar results (Fig. 2) . When smoke-treated C3 was examined by immunoelectrophoresis, it showed increased anodal migration similar to that of C3b (Fig. 3) . The smoke-induced change in electrophoretic mobility was not due to proteolytic cleavage of C3 because both the alpha and beta chains of smoke-treated C3 had an identical molecular weight as those of untreated, native C3 when analyzed by SDS-PAGE under reducing conditions (Fig.  4) . When NHS was treated with smoke solution (then dialyzed) and examined by immunoelectrophoresis against anti-C3, increased anodal migration of C3 was again observed (data not shown). The smoke-induced electrophoretic modification of C3 could not be reproduced by treating C3 with methylamine (Fig. 3) . In addition, the filtered gas phase of smoke and dialyzed whole smoke had no effect on the electrophoretic mobility of C3 (data not shown).
Effect of smoke on serum Cl and C4. To determine whether cigarette smoke solution could also activate the classical pathway, we examined the effect of smoke on Cl and C4 in whole serum. Cl activation was assessed by the radial immu- (1) Fig. 5 shows that incubation of serum with smoke solution did not result in a loss of antiCIr reactivity, which was identical to that observed using buffered-treated serum. These results were obtained in both single radial immunodiffusion (Fig. 5 A) and Ouchterlony double diffusion tests (Fig. 5 B) . In contrast, serum treated with aggregated IgG, a known activator of Cl and the classical pathway, showed a marked reduction in its reaction with antiClr in both tests (Figs. 5 A and B) . The effect of smoke on hemolytic levels of serum C4 is shown in Fig. 6 . Aqueous solutions of unfiltered cigarette smoke totally depleted C4 activity of serum, as did treatment with aggregated IgG. Serum incubated with buffer retained full C4 activity. Although this result appears to be in conflict with the preceeding data which indicated absence of classical pathway activation by cigarette smoke, the effect of smoke on serum C4 may be explained by the fact that an internal thiolester bond is present in this protein as well as in C3 (34) . This point will be discussed in further detail below.
Effect of smoke on C3 cleavage by Factors H and L Since it appeared that smoke treatment produced a modified form of C3 that is capable of activating the alternative pathway, we proceeded to test whether smoke-treated C3 was susceptible to inactivation by the complement regulatory proteins, Factors H and I. Factor H has the ability to bind to C3b and "C3b-like" C3 (a form of C3 activated by thiolester cleavage, e.g., NHS+AggIgG NHS+Smoke Figure 5 . Effect of whole smoke solution on serum Cl. NHS (0. Figure 6 . Hemolytic titration of serum C4. 0.05 ml of NHS was pretreated with either 0.05 ml of whole smoke solution (-* -), 0.02 ml of aggregated IgG (10 mg/ml) (-A----), or 0.05 ml of PBS (-o -) for 60 min at 370C. After pretreatment, the serum mixtures were diluted as indicated with SGVB2+, and 0.5 ml of each sample was then added to 0.2 ml of 1.5 X 108/ml EAC1 and incubated for 10 min at 370C. Next, 0.03 ml of C2 (20 ug/ml) was added to each sample and the incubation continued for 10 min at 370C. Finally, 2.2 ml of a 1:50 dilution of guinea pig serum containing 0.04 M EDTA in GVB was added and samples were incubated for an additional 60 min at 370C. The percent hemolysis was measured as absorbance of free hemoglobin at 412 nm. methylamine), but not to native C3. After binding, Factor H acts as a cofactor for proteolytic cleavage of the alpha chain of C3 by Factor I (35). Fig. 7 demonstrates that smoke-treated C3 showed partial cleavage of its alpha chain (lane 4) qualitatively similar to (but not quantitatively comparable with) methylamine-treated C3, in which there was substantial cleavage of the alpha chain to the predicted 76-and 43-kD fragments (lane 2). Under the same conditions, C3 treated with buffer (lane 6) showed almost no cleavage of its alpha chain. In the case of the buffer control, the small amount of cleavage observed was probably due to C3(H20), a "C3b-like" C3 that could have formed spontaneously during the incubation and dialysis period. Densitometric analysis of this gel revealed that alpha chain cleavage and appearance of the 76-and 43-kD products from C3 treated with smoke were intermediate in amount between those of methylamine and buffer-treated C3. Binding of radioiodinated Factor H to smoke-treated C3. Since smoke-treated C3 was not quantitatively comparable with methylamine-treated C3 with respect to alpha chain cleavage by Factors H and I, we chose next to test whether C3 treated with whole smoke solution was capable of binding 1251I Factor H. In this assay, the binding of Factor H is competitive between EC3b and fluid-phase "C3b-like" C3 (produced by methylamine treatment) or true C3b. The greater the binding of '251-Factor H to fluid-phase "C3b-like" C3 or C3b, the lower is its binding to EC3b. The data are given as percent of 100 ng of '25I-Factor H (0.5 mCi/ mg) bound to 5 X 107 EC3b in the presence of 2.0 jig of fluid-phase C3 competitors in a total volume of 0.1 ml in SGVB2+. The C3, EC3b, and I25I-Factor H mixtures were incubated for 10 min at room temperature. The mixtures were then layered onto 0.3 ml of 20% sucrose in SGVB2+; cells were then rapidly pelleted using a microfuge. (19, 20) . Such results, along with our preliminary report of complement-dependent increases in chemotactic activity in the lung washings of smoke-exposed rats (18) , raise the possibility that smoke- induced complement activation may also occur in humans. Should this prove true, chronic, low-grade activation of complement in the lung fluids of smokers could be an important initiating step in the pathogenesis of small airway inflammation in such individuals. Small airway inflammation, in turn, is thought to be a pathogenetic factor in the development of pulmonary emphysema (2, 3) . The factor(s) in cigarette smoke which deplete the hemolytic activity of serum and also produce a form of C3 that can activate the alternative pathway appear to have a mol wt < 1,000 and are found only in whole smoke. Numerous small nucleophiles, including methylamine and hydrazine (both of which can cleave thiolester bonds and produce "C3b-like" C3), are present in cigarette smoke (1, 36, 37) . One would expect these substances to be found in the gas phase of smoke, which we report to be inactive, but at the pH of cigarette smoke (-6.0), volatile amines are protonated and thus are found in the particulate phase (1). However, the observed effect of smoke on complement cannot be due to the action of these individual smoke components since their concentration in cigarette smoke is far too low to explain the results. For example, using the published values of 4.6 ,ug methylamine and 30 ng hydrazine/cigarette (1, 37), our smoke solution, prepared as described in Methods, contains -0.9 mM methylamine and 5.6 ,M hydrazine (compare these concentrations with the effective concentration range for methylamine shown in Figs. 1 and 2 ). In addition, ammonia, at concentrations found in cigarette smoke, had no effect on serum complement, although it has previously been reported that higher concentrations (50 mM) of ammonia resulted in 50% production of "C3b-like" C3 after a 60-min incubation (31) .
C3 treated with smoke, like methylamine-treated C3, has no change in molecular weight as determined by SDS-PAGE. In contrast to methylamine treatment, smoke-treated C3 has increased anodal mobility in agarose electrophoresis, indicating a more negatively charged molecule. Whether this is due to a secondary (artifactual) effect of cigarette smoke or is essential for the smoke-induced activating capacity of C3 is currently being investigated. Smoke (34) , cigarette smoke may directly consume C4 by cleaving its thiolester without activating the classical pathway. Alternatively, since C3 and C4 share a considerable degree of homology in the primary sequence of their alpha chains (38, 39), this could render both molecules susceptible to smoke-induced modifications by a thiolesterindependent mechanism. Such possibilities remain to be tested.
We have shown that exposure of C3 to smoke solution produces a functionally modified form of the molecule which is capable of activating the alternative pathway of complement. It remains unclear whether this smoke-modified C3 is similar to methylamine-treated C3 in that its internal thiolester bond is broken or whether smoke treatment produces a heretofore unrecognized form of C3 which has the ability to activate the alternative pathway without cleavage of its thiolester. Clearly, however, smoke-treated C3 is not identical to methylaminetreated C3.
Cigarette smoke is a complex mixture of over 4,000 known chemicals (1, 36) . We are currently attempting to fractionate smoke to separate possible complement activators from other "interfering" components. Future studies with isolated fractions of cigarette smoke may enable us to identify the chemical mechanism involved in smoke-induced complement activation.
